glp 1 naperville Real talk about GLP-1 success 💪 "It's not a miracle drug - you have to work with it." Weight Management / GLP-1 Therapy

Retatrutide Clinical Research Findings The clinical development program for retatrutide has produced compelling data across multiple research endpoints: Weight Loss Efficacy: Phase 2 trials showed dose-dependent weight reduction ranging from 8.7% at the lowest dose to 24.2% at the highest dose over 48 weeks Metabolic Improvements: Participants demonstrated improvements in glycemic control, lipid profiles, and blood pressure measurements Safety Profile: Gastrointestinal effects (nausea, vomiting, diarrhea) were the most common adverse events, occurring in 60-80% of participants but generally rated as mild to moderate in severity Sustained Effects: Weight loss continued throughout the trial period without evidence of plateau, suggesting ongoing metabolic benefits These findings have positioned retatrutide as a leading candidate for advanced metabolic research

and announced Medicare GLP-1 Bridge program details for 2026

How we reviewed this article: FDA (2024)

03 Effect & function: What does the tripeptide do in the body and why is it so important